Haemonetics Corp.
HAE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.99B
Close$
$122.25
33.8% upside
Current Fair Value
33.8% upsideUndervalued by 33.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.99 Billion |
|---|---|
| Enterprise Value | $4.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.05 |
| Beta | 0.52 |
| Outstanding Shares | 45,361,000 |
Return
| Return on Equity | 11.50% |
|---|---|
| Return on Assets | 4.07% |
| Return on Invested Capital | 7.19% |
Valuation & Multiples
| P/E Ratio | 42.64 |
|---|---|
| PEG | -1421.26 |
| Price to Sales | 3.15 |
| Price to Book Ratio | 5.07 |
| Enterprise Value to Revenue | 3.66 |
| Enterprise Value to EBIT | 32.7 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 1.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.08
Average shareholder expectationRevenue Estimate
$327.86 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.30
Average shareholder expectationRevenue Estimate
$345.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 42.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.43%▼ 72.60% |
|---|---|
| Total Invested | $1.05B▼ 60.81% |
| Investors Holding | 136▼ 196.00% |
ESG Score
No data
About Haemonetics Corp.
CEO: Christopher Simon